An In Silico Approach Towards Investigation of Possible Effects of Essential Oils Constituents on Receptors Involved in Cardiovascular Diseases (CVD) and Associated Risk Factors (Diabetes Mellitus and Hyperlipidemia)

Azadeh       Hamedi; Amirhossein       Sakhteman; Seyed    Mahmoud    Moheimani

doi:10.2174/1871524920666200510013039

Abstract

Aim: Aromatherapy products, hydrosol beverages and distillates containing essential oils are widely used for cardiovascular conditions. Investigation of the possible activity of their major constituents with the cardiovascular-related receptors may lead to developing new therapeutics. It also may prevent unwanted side effects and drug-herb interactions.

Materials and Methods: A list of 243 volatile molecules (mainly monoterpene and sesquiterpene) was prepared from a literature survey in Scopus and PubMed (2000-2019) on hydrosols and essential oils which are used for Cardiovascular Diseases (CVD) and its risk factors (diabetes mellitus and hyperlipidemia). The PDB files of the receptors (229 native PDB files) included alpha-glucosidase, angiotensin- converting enzymes, beta-2 adrenergic receptor, glucocorticoid, HMG-CoA reductase, insulin, mineralocorticoid, potassium channel receptors and peroxisome proliferator-activated receptoralpha, were downloaded from Protein Data Bank. An in silico study using AutoDock 4.2 and Vina in parallel mode was performed to investigate possible interaction of the molecules with the receptors. Drug likeliness of the most active molecules was investigated using DruLiTo software.

Results: Spathulenol, bisabolol oxide A, bisabolone oxide, bergapten, bergamotene, dill apiole, pcymene, methyl jasmonate, pinocarveol, intermedeol, α-muurolol, S-camphor, ficusin, selinen-4-ol, iso-dihydrocarveol acetate, 3-thujanone, linanool oxide and cadinol isomers made a better interaction with some of the named receptors. All of the named molecules had an acceptable dug likeliness except for α-bergamotene. In addition, all of the named molecules had the ability to pass the bloodbrain barrier and it is possible to produce unwanted side effects.

Conclusion: Some ingredients of essential oils might be active on cardiovascular-related receptors.

Keywords: Cardiovascular, diabetes mellitus, essentials oil, medicinal plant, receptor, traditional persian medicine.

« Previous Next »

Graphical Abstract

[1] 
Shanthi, M.; Pekka, P.; Bo, N. Global atlas on cardiovascular disease prevention and control- Policies, strategies and interventions; World Health Organization: Geneva, 2011. 
[2] 
(WHO), W.H.O.. Cardiovasc. Dis., 2018.
[3] 
Hamedi, A.; Ghanbari, A.; Razavipour, R.; Saeidi, V.; Zarshenas, M.M.; Sohrabpour, M.; Azari, H. Alyssum homolocarpum seeds: phytochemical analysis and effects of the seed oil on neural stem cell proliferation and differentiation. J. Nat. Med.,  2015, 69(3), 387-396.
[http://dx.doi.org/10.1007/s11418-015-0905-9] [PMID:  25860174] 
[4] 
Hamedi, A.; Farjadian, S.; Karami, M.R. Immunomodulatory properties of Trehala manna decoction and its isolated carbohydrate macromolecules. J. Ethnopharmacol.,  2015, 162, 121-126.
[http://dx.doi.org/10.1016/j.jep.2014.12.064] [PMID:  25571848] 
[5] 
Pasdaran, A.; Hamedi, A. The genus Scrophularia: A source of iridoids and terpenoids with a diverse biological activity. Pharm. Biol.,  2017, 55(1), 2211-2233.
[http://dx.doi.org/10.1080/13880209.2017.1397178 ] [PMID:  29125010] 
[6] 
Hamedi, A.; Ghanati, F.; Vahidi, H. Study on the effects of different culture conditions on the morphology of Agaricus blazei and the relationship between morphology and biomass or EPS production. Ann. Microbiol.,  2012, 62, 699-707.
[http://dx.doi.org/10.1007/s13213-011-0309-3] 
[7] 
Liperoti, R.; Vetrano, D.L.; Bernabei, R.; Onder, G. Herbal medications in cardiovascular medicine. J. Am. Coll. Cardiol.,  2017, 69(9), 1188-1199.
[http://dx.doi.org/10.1016/j.jacc.2016.11.078] [PMID:  28254182] 
[8] 
Richard, W.; Brian, T. Cardiovascular Disease. Herbal medicine: Biomolecular and clinical aspects; CRC Press: Boca Raton, FL, 2011. 
[9] 
Saljoughian, S.; Roohinejad, S.; Bekhit, A.E.A.; Greiner, R.; Omidizadeh, A.; Nikmaram, N.; Mousavi Khaneghah, A. The effects of food essential oils on cardiovascular diseases: A review. Crit. Rev. Food Sci. Nutr.,  2018, 58(10), 1688-1705.
[http://dx.doi.org/10.1080/10408398.2017.1279121 ] [PMID:  28678524] 
[10] 
Santos, M.R.; Moreira, F.V.; Fraga, B.P.; Souza, D.P.d.; Bonjardim, L.R.; Quintans-Junior, L.J. Cardiovascular effects of monoterpenes: A review. Rev. Bras. Farmacogn.,  2011, 21, 764-771.
[http://dx.doi.org/10.1590/S0102-695X2011005000119] 
[11] 
Forbes, R.J. A short history of the art of distillation: from the beginnings up to the death of Cellier Blumenthal; Brill: Netherlands, 1970. 
[12] 
Hamedi, A.; Moheimani, S.M.; Sakhteman, A.; Etemadfard, H.; Moein, M. An overview on indications and chemical composition of aromatic waters (hydrosols) as functional beverages in Persian nutrition culture and folk medicine for hyperlipidemia and cardiovascular conditions. J. Evid. Based Complementary Altern. Med.,  2017, 22(4), 544-561.
[http://dx.doi.org/10.1177/2156587216686460] [PMID:  29228785] 
[13] 
Hamedi, A.; Pasdaran, A.; Zebarjad, Z.; Moein, M. A survey on chemical constituents and indications of aromatic waters soft drinks (hydrosols) used in persian nutrition culture and folk medicine for neurological disorders and mental health. J. Evid. Based Complementary Altern. Med.,  2017, 22(4), 744-752.
[http://dx.doi.org/10.1177/2156587217714145] [PMID:  28633539] 
[14] 
Pasdaran, A.; Pasdaran, A.; Mamedov, N. Antibacterial and antioxidant activities of the volatile composition of the flower and fruit of Solanum sisymbriifolium (Litchi tomato). Pharm. Sci.,  2017, 23, 66.
[http://dx.doi.org/10.15171/PS.2017.10] 
[15] 
Lashgari, A.P.; Delazar, A.; Afshar, F.H.; Parsa, D. Contact toxicity and chemical composition of essential oil of Acantholimon scorpius. Pharm. Sci.,  2016, 22, 138.
[http://dx.doi.org/10.15171/PS.2016.22] 
[16] 
Al-Snafi, A.E. Therapeutic properties of medicinal plants: a review of plants with cardiovascular effects (part 1). Int. J. Pharmacol. Toxicol.,  2015, 5, 163-176.
[17] 
Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J.P. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res.,  2012, 40, D1100-D1107.
[http://dx.doi.org/10.1093/nar/gkr777] [PMID:  21948594] 
[18] 
Ghorbani, M.; Gohari, A.; Sakhteman, A.; Rezaei, Z. Iin silico analysis of drug resistance in HIV-reverse transcriptase inhibitors. ACTA Medica. Mediterr.,  2017, 33, 745-749.
[19] 
Burger, A.; Abraham, D.J. Burger’s medicinal chemistry and drug discovery; Wiley, 2003. 
[20] 
Emami, L.; Sabet, R.; Sakhteman, A.; Zade, M.K. Quantitative structure-activity relationship and molecular docking studies of imidazolopyrimidine amides as potent dipeptidyl peptidase-4 inhibitors. J. Pharmaceut. Res. Int.,  2019, 1-15.
[21] 
Sakhteman, A.; Khoddami, M.; Negahdaripour, M.; Mehdizadeh, A.; Tatar, M.; Ghasemi, Y. Exploring 3D structure of human gonadotropin hormone receptor at antagonist state using homology modeling, molecular dynamic simulation, and cross-docking studies. J. Mol. Model.,  2016, 22(9), 225.
[http://dx.doi.org/10.1007/s00894-016-3091-0] [PMID:  27561920] 
[22] 
Setlur, A.S.; Naik, S.Y.; Skariyachan, S. Herbal lead as ideal bioactive compounds against probable drug targets of Ebola virus in comparison with known chemical analogue: A computational drug discovery perspective. Interdiscip. Sci.,  2017, 9(2), 254-277.
[http://dx.doi.org/10.1007/s12539-016-0149-8] [PMID:  26857866] 
[23] 
Riordan, J.F. Angiotensin-I-converting enzyme and its relatives. Genome Biol.,  2003, 4(8), 225.
[http://dx.doi.org/10.1186/gb-2003-4-8-225] [PMID:  12914653] 
[24] 
Lambert, D.W.; Hooper, N.M.; Turner, A.J. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem. Pharmacol.,  2008, 75(4), 781-786.
[http://dx.doi.org/10.1016/j.bcp.2007.08.012] [PMID:  17897633] 
[25] 
Dinh, D.T.; Frauman, A.G.; Johnston, C.I.; Fabiani, M.E. Angiotensin receptors: Distribution, signalling and function. Clin. Sci. (Lond.),  2001, 100(5), 481-492.
[http://dx.doi.org/10.1042/cs1000481] [PMID:  11294688] 
[26] 
Pedersen-Bjergaard, U.; Agerholm-Larsen, B.; Pramming, S.; Hougaard, P.; Thorsteinsson, B. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet,  2001, 357(9264), 1248-1253.
[http://dx.doi.org/10.1016/S0140-6736(00)04405-6 ] [PMID:  11418149] 
[27] 
Strauss, M.H.; Hall, A.S. The divergent cardiovascular effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in adult patients with type 2 diabetes mellitus. Can. J. Diabetes,  2018, 42(2), 124-129.
[http://dx.doi.org/10.1016/j.jcjd.2017.09.011] [PMID:  29277343] 
[28] 
Cheng, J.; Zhang, W.; Zhang, X.; Han, F.; Li, X.; He, X.; Li, Q.; Chen, J. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: A meta-analysis. JAMA Intern. Med.,  2014, 174(5), 773-785.
[http://dx.doi.org/10.1001/jamainternmed.2014.348 ] [PMID:  24687000] 
[29] 
Johnson, M. Molecular mechanisms of β(2)-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol.,  2006, 117(1), 18-24.
[http://dx.doi.org/10.1016/j.jaci.2005.11.012] [PMID:  16387578] 
[30] 
Najafi, A.; Sequeira, V.; Kuster, D.W.; van der Velden, J. β-adrenergic receptor signalling and its functional consequences in the diseased heart. Eur. J. Clin. Invest.,  2016, 46(4), 362-374.
[http://dx.doi.org/10.1111/eci.12598] [PMID:  26842371] 
[31] 
Galvan, D.L.; Danesh, F.R. β2-adrenergic receptors in inflammation and vascular complications of diabetes. Kidney Int.,  2017, 92(1), 14-16.
[http://dx.doi.org/10.1016/j.kint.2017.03.024] [PMID:  28646990] 
[32] 
Brodde, O-E.; Bruck, H.; Leineweber, K. Cardiac adrenoceptors: Physiological and pathophysiological relevance. J. Pharmacol. Sci.,  2006, 100(5), 323-337.
[http://dx.doi.org/10.1254/jphs.CRJ06001X] [PMID:  16612046] 
[33] 
Kalra, S. Alpha glucosidase inhibitors. J. Pak. Med. Assoc.,  2014, 64(4), 474-476.
[PMID:  24864650] 
[34] 
Rose, D.R.; Chaudet, M.M.; Jones, K. Structural studies of the intestinal α-glucosidases, maltase-glucoamylase and sucrase-isomaltase. J. Pediatr. Gastroenterol. Nutr.,  2018, 66, S11-S13.
[http://dx.doi.org/10.1097/MPG.0000000000001953 ] [PMID:  29762369] 
[35] 
Santos, R.M.M.; Lima, D.R.A. Coffee consumption, obesity and type 2 diabetes: A mini-review. Eur. J. Nutr.,  2016, 55(4), 1345-1358.
[http://dx.doi.org/10.1007/s00394-016-1206-0] [PMID:  27026242] 
[36] 
Ward, C.W.; Lawrence, M.C. Ligand-induced activation of the insulin receptor: A multi-step process involving structural changes in both the ligand and the receptor. BioEssays,  2009, 31(4), 422-434.
[http://dx.doi.org/10.1002/bies.200800210] [PMID:  19274663] 
[37] 
Belfiore, A.; Malaguarnera, R.; Vella, V.; Lawrence, M.C.; Sciacca, L.; Frasca, F.; Morrione, A.; Vigneri, R. Insulin receptor isoforms in physiology and disease: An updated view. Endocr. Rev.,  2017, 38(5), 379-431.
[http://dx.doi.org/10.1210/er.2017-00073] [PMID:  28973479] 
[38] 
Goodwin, J.E.; Geller, D.S. Glucocorticoid-induced hypertension. Pediatr. Nephrol.,  2012, 27(7), 1059-1066.
[http://dx.doi.org/10.1007/s00467-011-1928-4] [PMID:  21744056] 
[39] 
Di Dalmazi, G.; Pagotto, U.; Pasquali, R.; Vicennati, V. Glucocorticoids and type 2 diabetes: From physiology to pathology. J. Nutr. Metab., 2012.2012525093
[http://dx.doi.org/10.1155/2012/525093] [PMID:  23316348] 
[40] 
Lu, N.Z.; Wardell, S.E.; Burnstein, K.L.; Defranco, D.; Fuller, P.J.; Giguere, V.; Hochberg, R.B.; McKay, L.; Renoir, J-M.; Weigel, N.L.; Wilson, E.M.; McDonnell, D.P.; Cidlowski, J.A. The pharmacology and classification of the nuclear receptor superfamily: Glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol. Rev.,  2006, 58(4), 782-797.
[http://dx.doi.org/10.1124/pr.58.4.9] [PMID:  17132855] 
[41] 
Thompson, A.; Arany, E.J.; Hill, D.J.; Yang, K. Glucocorticoid receptor expression is altered in pancreatic beta cells of the non-obese diabetic mouse during postnatal development. Metabol.,  2002, 51(6), 765-768.
[http://dx.doi.org/10.1053/meta.2002.32033] [PMID:  12037732] 
[42] 
Whorwood, C.B.; Donovan, S.J.; Flanagan, D.; Phillips, D.I.; Byrne, C.D. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes,  2002, 51(4), 1066-1075.
[http://dx.doi.org/10.2337/diabetes.51.4.1066] [PMID:  11916927] 
[43] 
Cha, D.R.; Zhang, X.; Zhang, Y.; Wu, J.; Su, D.; Han, J.Y.; Fang, X.; Yu, B.; Breyer, M.D.; Guan, Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes,  2007, 56(8), 2036-2045.
[http://dx.doi.org/10.2337/db06-1134] [PMID:  17536062] 
[44] 
Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today. Technol.,  2004, 1(4), 337-341.
[http://dx.doi.org/10.1016/j.ddtec.2004.11.007] [PMID:  24981612] 
[45] 
Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev.,  2001, 46(1-3), 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0 ] [PMID:  11259830] 
[46] 
Banks, W.A. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol.,  2009, 9, S3-S3.
[http://dx.doi.org/10.1186/1471-2377-9-S1-S3] [PMID:  19534732] 

Rights & Permissions Print Cite

Article Metrics

19

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871524920666200510013039	Print ISSN 1871-5257
Publisher Name Bentham Science Publisher	Online ISSN 1875-6182

Cardiovascular & Hematological Agents in Medicinal Chemistry

An In Silico Approach Towards Investigation of Possible Effects of Essential Oils Constituents on Receptors Involved in Cardiovascular Diseases (CVD) and Associated Risk Factors (Diabetes Mellitus and Hyperlipidemia)

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract